If mutations in a given gene or pathway are seen in a large enough fraction of a given tumor histology, it brings attention to that gene/pathway as having a possible critical role in the disease under study—with BCR-ABL in CML and BRAF in melanoma the two best examples [46, 47]. The gene discussed is BRAF; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.